Heart Health and COVID-19: Could CBD Offer Some Relief?
July 15th, 2020
It is no secret that people with underlying health conditions are the most vulnerable potential COVID-19 patients. Prominent among these hazardous underlying conditions is heart disease. According to the Centers for Disease Control, patients with heart failure, coronary artery disease, and other heart conditions are particularly at risk for severe illness from the virus.
The connection between COVID-19 and the heart is, along with many other aspects of this novel disease, slowly coming into focus. There is mounting evidence that COVID-19 may also produce heart injury in patients, and excessive inflammation (sometimes resulting in a fatal cytokine storm) may be the culprit. This scientific article lays out the case pretty clearly: treating heart inflammation is a key to avoiding catastrophic results.
There is one Canadian company, already focused on developing therapies for heart conditions, clearly forging ahead in this area. Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) filed a new patent application covering the use of cannabidiol (CBD) to improve the outcome of patients with COVID-19. Cardiol has already planned to study CBD as a primary active in the treatment for heart failure and acute myocarditis. With all of the evidence surrounding heart disease and negative COVID-19 outcomes, the company is naturally progressing its research to determine whether CBD can help a) improve outcomes for patients with pre-existing heart conditions or risk factor for heart disease, and b) decrease the occurrence of cardiovascular complications in such patients.
Inflammation is the Enemy
Chronic heart failure (HF) is common, with an estimated six million adults suffering from the disease in Canada and the United States. Approximately 50% of patients with HF have a condition known as HF with preserved ejection fraction (HFpEF), wherein the contraction of the heart remains relatively normal, but there is an abnormality in the filling of the heart during the relaxation phase. Over the last twenty years, there have been no major advancements in the treatment of this form of HF. Current standard of care is the use of diuretics to decrease inflammation, and there is no known cure. Inflammation in the heart tissue leads to increased production of cytokines, increased oxidative stress, death of heart cells, and eventually to the creation of fibrosis, which leads to increased stiffness of the heart tissues that further exacerbates the problem. In this way, the body creates a destructive inflammatory feedback loop. It is similar to the way doctors discuss the often-fatal cytokine storms resulting from COVID-19.
Acute myocarditis is another problematic form of heart disease and is the most common cause of sudden cardiac death in people under the age of 35. It is most often caused by a viral infection followed by the body’s inflammatory response, similar in many ways to what doctors are seeing with COVID-19 patients.
Cardiol is advancing studies on the efficacy of targeted CBD treatments for both of these heart conditions. The targeting mechanism consists of proprietary nanotherapeutics technology that enables water-insoluble drugs (like fat-based CBD) to be distributed in the bloodstream and accumulate in the affected heart tissues. In March, the company’s researchers presented evidence that these nanoparticles accumulated in diseased heart tissues in excess of 100 times more than in the healthy control group. Clearly, Cardiol has the technology to effectively deliver active pharmaceutical ingredients to targeted tissues.
With the decades-long prohibition of cannabis and minimal scientific research into the plant, there is a lot to be discovered about the potential benefits of the wide variety of active ingredients, called cannabinoids, prevalent in cannabis. One in particular, cannabidiol (CBD), has shown potential for treating conditions ranging from epilepsy to sleep disorders to PTSD. It is available in copious amounts from both cannabis and hemp plants and is not psychoactive.
Research shows that “CBD reduces the levels of pro-inflammatory cytokines, inhibits T cell proliferation, induces T cell apoptosis, and reduces migration and adhesion of immune cells.” These are just the types of actions needed to treat heart disease, as well as to mitigate an over-responsive immune system. Here are some more sources for research on the topics of heart failure, inflammation, and CBD.
Cardiol Putting It Together
Cardiol Therapeutics is combining a number of threads to attack heart disease, and now COVID-19. It starts with the experienced team dedicated to improving heart patient outcomes. The company is partnering with key international research organizations, including the renowned Houston Methodist DeBakey Heart & Vascular Center. Cardiol also partners with Purisys, LLC and Dalton Pharma Services for the formulation and production of its own proprietary pure pharmaceutical CBD, which it uses in its research and plans to launch commercially to Canadian medical cannabis patients.
The nanotechnology ensures targeted delivery of the CBD to affected tissues, overcoming a common problem of cannabinoid and other lipid-based therapies. The CBD it uses is produced in cGMP and FDA-approved facilities, legitimizing the drug, and perhaps increasing the chances it could be approved should the research bear fruit. The recent intellectual property filing could serve to protect Cardiol should it find, as preliminary research indicates, that its CBD therapies help those with heart conditions, and by extension help COVID-19 patients achieve better outcomes.
A look at the development of some comparable companies can shine some light on Cardiol’s potential. GW Pharma’s cannabis-derived Epidiolex was approved by the FDA in 2018 for the treatment of two rare forms of epilepsy. The company had previously introduced Sativex, a cannabis-derived oral spray for the relief of multiple sclerosis (MS) symptoms and cancer-related neuropathic pain. GW’s incremental success in developing and getting approval for these drugs led to stock appreciation from $10 in the summer of 2013, to a high of about $180 in May 2019 (currently around $130).
More recently, and in the heart disease arena, MyoKardia announced positive Phase 3 results for its candidate to treat obstructive hypertrophic cardiomyopathy (HCM). The announcement triggered a run up of the company’s stock, from approximately $60 to $120 (currently around $90). Earlier results had similar effects, with Phase 1 safety trials pushing the stock from $10 to $20, followed by Phase 2 results catapulting the stock over $40 in 2017.
Cardiol recently closed a financing of $17.25 million, intended to support its clinical development program as well as the commercial launch of its pharmaceutical CBD product. The company also brought on noted CNBC Fast Money commentator Steven Grasso as business advisor to raise its profile in the U.S. investment community. The table is set. Keep an eye out for further developments from Cardiol Therapeutics as the company seeks to emulate the success of its peers in both the heart and CBD fields.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.